Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC

Journal:

Nature Communications

Published:

2026-02-24

DOI:

10.1038/s41467-026-69695-4

Affiliations:

6

Authors:

10

Go to article

Institutions	Authors	Share
State Key Laboratory of Molecular Oncology, China	6.000000	0.60
University of California, San Diego (UC San Diego), United States of America (USA)	1.000000	0.10
Johns Hopkins University (JHU), United States of America (USA)	1.000000	0.10
Mayo Clinic, United States of America (USA)	1.000000	0.10
Hubei Hongshan Laboratory, China	0.500000	0.05
Huazhong Agricultural University (HZAU), China	0.500000	0.05

Interested in Oncology and Carcinogenesis?